Genitourinary Cancers | Specialty

FDA Approves TAS-102, New Nivolumab Breakthrough Designation, Two Priority Reviews, and More

September 25th 2015

Nivolumab Extends Survival in Advanced Renal Cell Carcinoma

September 25th 2015

Nivolumab reduced the risk of death by 27% versus everolimus in patients with advanced renal cell carcinoma, improving overall survival by 5.4 months.

Second-Line Cabozantinib Improves PFS in Advanced RCC

September 25th 2015

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

PD-1 and PD-L1 May Be Actionable Targets in Sarcomatoid Renal Cell Carcinoma

September 21st 2015

Renal cell carcinoma with sarcomatoid differentiation, a histology that is often resistant to targeted therapies and interleukin-2 immunotherapy (IL-2), may respond to anti–PD-1/PD-L1 therapies.

Axitinib Dose Titration Improves Outcomes in Metastatic Renal Cell Carcinoma

September 16th 2015

Titrating dose levels of axitinib (Inlyta) improved response rates and extended overall survival by 12.3 months in patients with metastatic renal cell carcinoma.

FDA Grants Nivolumab Breakthrough Designation in Renal Cell Carcinoma

September 16th 2015

Nivolumab (Opdivo) has received an FDA breakthrough therapy designation for the treatment of patients with advanced renal cell carcinoma.

Dr. Larkin on Lenvatinib Plus Everolimus in Patients With RCC

September 15th 2015

James Larkin, MD, PhD, medical oncologist, Royal Marsden Hospital, discusses a phase II study that examined the combination of lenvatinib and everolimus versus either agent alone in patients with renal cell carcinoma.

FDA Grants Intravesical Immunotherapy Priority Review for Bladder Cancer

August 28th 2015

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Cabozantinib Granted FDA Breakthrough Designation in Renal Cell Carcinoma

August 24th 2015

Cabozantinib (Cometriq) has received a breakthrough therapy designation from the FDA for the treatment of patients with advanced renal cell carcinoma following one prior therapy.

Dr. Ko on Renal Transplantation Following Tumor Excision

August 12th 2015

Dicken Shiu-Chung Ko, MD, Department of Urology, Massachusetts General Hospital, discusses current evidence of renal transplantation following tumor excision.

Lenvatinib Breakthrough Designation, New Drug Applications for NSCLC, STS, and More

August 7th 2015

Role of Anti-PD-1/PD-L1 Immunotherapy in Bladder Cancer

August 3rd 2015

Results from clinical trials demonstrate that immunotherapy is ready to take center stage in the fight against bladder cancer.

FDA Grants Breakthrough Designation to Lenvatinib for Renal Cell Carcinoma

July 28th 2015

The FDA has granted a breakthrough therapy designation to lenvatinib as a potential treatment for patients with advanced renal cell carcinoma who have received a VEGF-targeted therapy.

Two Positive Phase III RCC Studies, Nivolumab Approved for NSCLC in Europe, and More

July 24th 2015

Optimizing Treatment in Renal Cell Carcinoma

July 21st 2015

Switching Therapies for Progressive Advanced RCC

July 21st 2015

Frontline Treatment Approaches in Advanced RCC

July 21st 2015

Adjuvant Therapy in High-Risk Renal Cell Carcinoma

July 21st 2015

Renal Cell Carcinoma Histologies

July 21st 2015

Promising Treatments on the Horizon for Advanced RCC

July 21st 2015